| Formulary Amendments |
| Last updated: 28th February 2025 |
| Chapter |
Change |
Traffic light
status |
Reason for change |
| 06.01.02.03 |
Liraglutide – brand names removed and changed to biosimilar. |
n/a |
NENC Medicines Committee (February 2025) |
| 06.01.02.03 |
Lixisenatide – removed from formulary as discontinued |
n/a |
NENC Medicines Committee (February 2025) |
| 04.01.01 |
Sodium oxybate 500mg/ml oral solution – brand name removed as generic lines now available |
 |
NENC Medicines Committee (February 2025) |
| 09.02.01.01 |
Potassium chloride (Kay-Cee-L) – deleted as no longer available |
n/a |
NENC Medicines Committee (February 2025) |
| 02.01.01 |
Digibfab® - indication updated to include cardiac glycoside poisoning |
|
NENC Medicines Committee (February 2025) |
| 05.01.01.01 |
Penicillin nomenclature updated |
n/a |
NENC Medicines Committee (February 2025) |
| 04.02.02 |
Paliperidone injection – note added that use of 6 monthly injections not supported by CNTW/TEWV |
n/a |
NENC Medicines Committee (February 2025) |
| 08.02.03 |
Ublituximab added as an option for treating relapsing forms of multiple sclerosis, defined as active by clinical or imaging features in adults in line with NICE |
|
TA1025 |
| 04.12 |
Eplontersen added as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy in line with NICE |
|
TA1020 |
| 08.01.03 |
Crovalimab added as an option for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over who weigh 40 kg or more in line with NICE |
|
TA1019 |
| 08.01.05 |
Fedratinib added as an option for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in line with NICE |
|
TA1018 |
| 08.01.05 |
Pembrolizumab updated for neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for resectable non-small-cell lung cancer (NSCLC) with a high risk of recurrence in adults in line with NICE. |
|
TA1017 |
| 01.09.01 |
Elafibranor added as an option for treating primary biliary cholangitis in adults in line with NICE |
|
TA1016 |
| 08.01.05 |
Teclistamab added as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on the last treatment in line with NICE. |
|
TA1015 |
| 08.01.05 |
Alectinib updated to add an option for the adjuvant treatment of stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after complete tumour resection in adults in line with NICE |
|
TA1014 |
| 08.01.05 |
Avapritinib added as an option for treating advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm and mast cell leukaemia) in adults in line with NICE. |
|
TA1012 |
| 08.01.05 |
Quizartinib added as an option for newly diagnosed FLT3‑ITD‑positive acute myeloid leukaemia (AML) in adults in line with NICE |
|
TA1013 |
| 08.01.05 |
Belzutifan added (with managed access) as an option for treating von Hippel-Lindau (VHL) disease in adults in line with NICE |
|
TA1011 |
| 09.01.03 |
Danicopan approved as an add-on to ravulizumab or eculizumab as an option for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults who have residual haemolytic anaemia in line with NICE |
|
TA1010 |
| 18.07.02 |
Appeel® Single use wipes changed from Green+ to Green |
 |
NENC Medicines Committee (February 2025) |
| 18.05 |
Debrisoft® changed from Green+ to Green |
|
NENC Medicines Committee (February 2025) |
| 18.03.02 |
Inadine dressings changed from Green to Green+ |
 |
NENC Medicines Committee (February 2025) |
| 18.05 |
Eakin ® Wound patches changed from Red to Green+ |
|
NENC Medicines Committee (February 2025) |
| 13.02.01 |
Aqueous cream now NOT approved |
 |
NENC Medicines Committee (February 2025) |
| 13.02.01 |
Emollients removed in line with recently approved guideline: Aveeno, Doublebase gel, E45, Epaderm emollient, Hydrous ointment, Oilatum cream, Oilatum junior cream, Paraffin sterile liquid, Calmurid. |
n/a |
NENC Medicines Committee (February 2025) |
| 13.02.01 |
Emollients added in line with recently approved guideline: Zerodouble gel, Isomol Gel, Emollin Spray, Zerobase cream, QV cream, Aquamax, Hydromol cream, Zeroderm ointment, Cetraben ointment, 50:50 liquid and WSP ointment, QV intensive ointment, Hydromol Intensive, Epimax oatmeal cream |
|
NENC Medicines Committee (February 2025) |
| 02.05.01 |
Tadalafil changed from Red to Green+ for Raynaud's |
|
NENC Medicines Committee (February 2025) |
|
04.08.01
|
Carbamazepine suppositories changed from Red to Green+ |
|
NENC Medicines Committee (February 2025) |
| 13.10.04 |
Ivermectin: indication for scabies added |
|
NENC Medicines Committee (February 2025) |
| 06.05.02 |
Demeclocycline status changed from Green+ to Red |
|
NENC Medicines Committee (February 2025)NENC Medicines Committee (February 2025) |
| 05.01.07 |
Fosfomycin 3g sachets now approved for primary care to prescribe for UTI without microbiology advice. |
|
NENC Medicines Committee (February 2025) |
| 07.01.01 |
Carbetocin added in response to Oxytocin NatPSA |
|
NENC Medicines Committee (February 2025) |
| 05.02.01 |
Itraconazole oral preparations changed from Green+ to Green |
|
NENC Medicines Committee (February 2025) |
| 07.03.02.01 |
Drospirenone (Slynd®) NOT approved. |
|
NENC Medicines Committee (February 2025) |
| 02.05.05.01 |
Enalapril orodispersible tablets (Aqumeldi®) added for the management of paediatric heart failure |
|
NENC Medicines Committee (February 2025) |
| 04.07.03 |
Onabotulinum toxin A (Botox®) indication for the treatment of myalgia temporomandibular disorders (M-TMD) and orofacial neuropathic pain (OFNP) added. |
|
NENC Medicines Committee (February 2025) |
| 06.04.01.02 |
Dienogest 2mg tablets added for the treatment of endometriosis in patients who have failed GnRH therapy. |
|
NENC Medicines Committee (February 2025) |
| 11.08.02 |
Bevacizumab gamma is added as an option for treating wet age-related macular degeneration in adults in line with NICE |
|
TA1022 |
| 11.06 |
Latanoprost–netarsudil is added as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension in line with NICE |
|
TA1009 |
| 13.05.03 |
Ritlecitinib is added as an option for treating severe alopecia areata in people 12 years and over in line with NICE |
|
TA958 |
| 06.01.06 |
Note added to Freestyle Libre 2 : DO NOT INITIATE IN NEW PATIENTS AS BEING DISCONTINUED IN SUMMER 2025 |
|
Discontinuation notice |
| 13.06.01 |
trifarotene (Aklief®) cream added as an alternative to other available retinoids in patients with facial and / or truncal acne, either in combination with other topical therapies, or as monotherapy where a fixed combination product is not tolerated, or one component is contraindicated. |
|
NENC Medicines Committee (April 2023) |
| 4 |
Tier 3 weight management services commissioning policy added to Chapter 4 and Semaglutide, Liraglutide entries |
n/a |
New NENC Policy |
| 04.10.02 |
Smoking Cessation Therapy: Cytisine is now referred to as Cytisinicline (Cytisine) |
|
BNF nomenclature |
| 14 |
The following vaccinations should not be prescribed on the NHS exclusively for the purposes of travel:
• hepatitis B • Japanese encephalitis • meningitis ACWY
• yellow fever • tick-borne encephalitis • rabies • BCG.
|
n/a |
NENC Medicines Committee (December 2024) |
| 04.07.02 |
Tramadol and paracetamol combination products now Not Approved for use, the BLACK status should primarily apply to new patients but, where appropriate, de-prescribing in existing patients should be undertaken. |
|
NENC Medicines Committee (December 2024) |
| 04.07.02 |
Oxycodone + Naloxone combination products now Not Approved. The BLACK status should primarily apply to new patients but, where appropriate, de-prescribing in existing patients should be undertaken. |
|
NENC Medicines Committee (December 2024) |
| 04.07.02 |
Fentanyl sublingual tablets (Abstral®) restricted to use for breakthrough / rescue pain relief in palliative care on recommendation of a pain specialist or palliative care team.
|
|
NENC Medicines Committee (December 2024) |
| 05.01.03 |
Minocycline for the treatrment of acne is Not Approved. Do not initiate for new patients and deprescribe where possible in existing patients |
|
NENC Medicines Committee (December 2024) |
| 09.08 |
Ubidecarenone DO NOT PRESCRIBE for new patients and where appropriate, undertake deprescribing in existing patients. Approval for use in lipid clinic removed. |
|
NENC Medicines Committee (December 2024) |
| 15.01.08 |
Dantrolene Sodium 120mg vial added |
|
NENC Medicines Committee (December 2024) |
| 01.02 |
Mebeverine 50mg/5ml Oral Suspension updated "Should only be used in patients unable to use solid dosage forms" |
|
NENC Medicines Committee (December 2024) |
| 04 |
All valproate containing products updated with new restrictions for male patients. |
|
NENC Medicines Committee (December 2024) |
| 07.03.02.03 |
(Levosert®) contraceptive indication updated to reflect 8 year effective duration |
|
NENC Medicines Committee (December 2024) |
| 06.04.01.02 |
Note added to both Norethisterone and Medroxyprogesterone "Should not be prescribed for menstrual delay for non clinical reasons" |
|
NENC Medicines Committee (December 2024) |
| 04.04 |
Methylphenidate 2mg/ml oral solution sugar free (Consilient Health Ltd) added. Only for those patients unable to take solid dosage forms across the whole dosage range. |
 |
NENC Medicines Committee (December 2024) |
| 09.06.07 |
Paravit-CF added for fat soluble vitamin supplementation in CF patients |
|
NENC Medicines Committee (December 2024) |
| 18.08.03 |
Skinnies® elasticated viscose garments added |
|
NENC Medicines Committee (December 2024) |
| 04.07.02 |
Sufentanil added for use during dressing changes in burns patients. |
|
NENC Medicines Committee (December 2024) |
| 08.01.03 |
Trifluridine and tipiracil updated to include indication for treating metastatic colorectal cancer in adults who have had 2 lines of treatment |
|
NICE TA1008 |
| 08.01.05 |
Rucaparib updated to include indication for maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults |
|
NICE TA1007 |
| 08.01.05 |
Futibatinib added for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement |
|
NICE TA1005 |
| 09.01 |
Exagamglogene Autotemcel added for treating transfusion-dependent beta-thalassaemia in people 12 years and over |
|
NICE TA1003 |
| 02.12 |
Evinacumab added for treating homozygous familial hypercholesterolaemia (HoFH) in people 12 years and over |
|
NICE TA1002 |
| 08.01.05 |
Zanubrutinib updated to include indication for treating marginal zone lymphoma in adults |
|
NICE TA1001 |
| 09.01.03 |
Iptacopan added for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with haemolytic anaemia |
|
NICE TA1000 |
| 07.04.02 |
Vibegron added for treating symptoms of overactive bladder syndrome in adults |
|
NICE TA999 |
|
01.05.03
|
Risankizumab updated to include indication for treating moderately to severely active ulcerative colitis in adults |
|
NICE TA998 |
| 08.01.05 |
Pembrolizumab updated to include indication for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma |
|
NICE TA997 |
| 06.07.02 |
Linzagolix added for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age |
|
NICE TA996 |
| 08.03.04.02 |
Relugolix added for treating prostate cancer in adults |
|
NICE TA995 |
| 06.06.02 |
Burosumab updated to include indication for treating X‑linked hypophosphataemia (XLH) in adults |
|
NICE TA993 |
| 06.06.01 |
Abaloparatide added for treating osteoporosis after menopause |
|
NICE TA991 |
| 04.03.01 |
Trimipramine now not to be initiated for new patients and deprescribed in existing patients where possible. |
|
NENC Medicines Committee (October 2024) |
| 18.08.03 |
Silk garments not approved for use |
|
NENC Medicines Committee (October 2024) |
| 10.03.02 |
Rubefacients not approved for use |
|
NENC Medicines Committee (October 2024) |
| 02.05.05.01 |
Perindopril Arginine not approved for use |
|
NENC Medicines Committee (October 2024) |
| 02.12 |
Omega-3 Fatty acid compounds (except Vazkepa) not approved for use |
|
NENC Medicines Committee (October 2024) |
| 09 |
Lutein and Antioxidants preparations not approved for use |
|
NENC Medicines Committee (October 2024) |
| 09 |
Glucosamine and Chondroitin not approved for use. |
|
NENC Medicines Committee (October 2024) |
| 02.05.04 |
Doxazosin MR not approved for use. |
|
NENC Medicines Committee (October 2024) |
| 04.03.01 |
Dosulepin now not to be initiated for new patients and deprescribed in existing patients where possible. |
|
NENC Medicines Committee (October 2024) |
| 04.07.01 |
Co-proxamol now classed as a medicines of low clinical value |
|
NENC Medicines Committee (October 2024) |
| 13.02.01 |
Bath and shower preparations for dry and pruritic skin conditions classed as medicines of low clinical value |
|
NENC Medicines Committee (October 2024) |
| 02.05.05.03 |
Aliskiren now classed as a medicine of low clinical value |
|
NENC Medicines Committee (October 2024) |
| 05.02.01 |
Off label indication for treatment of non-invasive fungal infections using the voriconazole 100mg tablets ONLY |
|
NENC Medicines Committee (October 2024) |
| 02.08.02 |
Following statement added to all DOAC listings: "In the absence of a specific clinical reason to select a particular DOAC, choose the most effective DOAC first. Rivaroxaban 'cost effective once daily for non-valvular AF' and Apixaban 'cost effective twice daily choice for non-valvular AF' " |
|
NENC Medicines Committee (October 2024) |
| 13.04.01 |
Removal of calcipotriol scalp solution as now discontinued |
|
NENC Medicines Committee (October 2024) |
| 06.04.02 |
Removal of tradename (Nebido) from testosterone undecanoate 1g/4ml as generics now available |
|
NENC Medicines Committee (October 2024) |
| 01.06.07 |
Prucalopride RAG status changed from GREEN to GREEN+ |
|
NENC Medicines Committee (October 2024) |
| 07.02.01 |
Removal of trademark from estriol 1mg/g (0.1%) cream and clarification of dosage statement |
|
NENC Medicines Committee (October 2024) |
| 01 |
Atropine 500microgram in 5ml mixture removed from formulary |
|
NENC Medicines Committee (October 2024) |
| 11.06 |
Latanoprost 0.005% with Timolol 0.5% eye drops preservative free (Fixapost) added as a PF option |
|
NENC Medicines Committee (October 2024) |
| 04.06 |
Additional off-license indication (use in children under 12yrs / longer term use, when required, for the prevention of nausea and vomiting in paediatric patients undergoing haematopoietic stem cell transplantation (HSCT)) added to aprepitant 80mg and 125mg capsules |
|
NENC Medicines Committee (October 2024) |
| 04.10.02 |
Smoking Cessation Therapy entry to replace individual NRT products |
|
NENC Medicines Committee (October 2024) |
| 04.12 |
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy |
|
NICE TA984 |
| 08.01.05 |
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (not recommended) |
|
NICE TA983 |
| 10.01.03 |
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) |
|
NICE TA982 |
| 08.01.05 |
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation |
|
NICE TA979 |
| 11.08.02 |
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion |
|
NICE TA1004 |
| 07.04.02 |
North of Tyne, Gateshead & North Cumbria: Urinary Continence Enablement Products and Devices Formulary 2024 |
|
NENC Guidelines Group (October 2024) |
| 04.07 |
NENC Clinical Pain Network: Position Statement on Chronic Pain Guidelines |
|
NENC Guidelines Group (October 2024) |
| 06.04.01.01 |
NENC ICB-wide Menopause guidance - update |
|
NENC Guidelines Group (October 2024) |
| 09.05.01.03 |
NENC ICB-wide Management of Hypomagnesaemia in adults |
|
NENC Guidelines Group (October 2024) |
| 09.04 |
NENC ICB-wide Guidelines for the appropriate prescribing of Oral Nutritional Supplementation in the management of adults at risk of undernutrition in primary care |
|
NENC Guidelines Group (October 2024) |
| 13.02.01 |
NENC ICB-wide Emollient Prescribing Guideline and Formulary added |
|
NENC Guidelines Group (October 2024) |
| 08.01.05 |
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (not recommended) |
|
NICE TA992 |
| 02.11 |
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B |
|
NICE TA989 |
| 08.01.05 |
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) |
|
NICE TA987 |
| 13.05.03 |
Lebrikizumab for treating moderate to severe atopic dermatitis |
|
NICE TA986 |
| 19 |
QuiremSpheres for treating unresectable advanced hepatocellular carcinoma |
|
NICE TA985 |
| 01.05.03 |
Risankizumab for treating moderately to severely active ulcerative colitis |
|
NICE TA998 |
| 02.05.01 |
Sildenafil - amendment of secondary Raynaud's to Raynaud's |
|
NENC Medicines Committee (August 2024) |
| 02.10.02 |
Tenecteplase for treating acute ischaemic stroke |
|
NICE TA990 |
| 03.09.01 |
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) |
|
NICE TA969 |
| 04.01.01 |
Daridorexant - addition of NHCFT to list of providers |
|
NENC Medicines Committee (August 2024) |
| 04.03.03 |
Fluoxetine 10mg capsules - addition of formulation |
|
NENC Medicines Committee (August 2024) |
| 04.06 |
Doxylamine & pyrodoxine for use in nausea and vomiting in pregnancy |
|
NENC Medicines Committee (August 2024) |
| 04.07.02 |
Morphine sulfate oro-dispersible tablets (Actimorph) added and Sevredol removed |
|
NENC Medicines Committee (August 2024) |
| 04.07.04.02 |
Atogepant for preventing migraine |
|
NICE TA973 |
| 05 |
Addition of link for cellulitis diagnosis and management |
|
NENC Medicines Committee (August 2024) |
| 05.03.01 |
Addition of bictegravir, emtricitabine, tenofovir alafenamide (Biktarvy®) |
|
Correction of missing entry |
| 06.03.02 |
Hydrocortisone oral solution & merged entries |
|
NENC Medicines Committee (August 2024) |
| 06.04.01.02 |
Progesterone - Addition of Utrogestran vaginal capsules and clarification of use in relation to NICE NG25 |
|
NENC Medicines Committee (August 2024) |
| 06.07 |
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome |
|
NICE HST31 |
| 07.04.02 |
Vibegron for treating symptoms of overactive bladder syndrome |
|
NICE TA999 |
| 08.01.05 |
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma |
|
NICE TA964 |
| 08.01.05 |
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over |
|
NICE TA977 |
| 08.01.05 |
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency |
|
NICE TA963 |
| 08.01.05 |
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) |
|
NICE TA968 |
| 08.01.05 |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over |
|
NICE TA967 |
| 08.01.05 |
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) |
|
NICE TA966 |
| 08.01.05 |
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma |
|
NICE TA974 |
| 08.01.05 |
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) |
|
NICE TA976 |
| 08.01.05 |
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) |
|
NICE TA978 |
| 08.02.02 |
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) |
|
NICE TA972 |
| 09.01.01.01 |
Addition of position statement for oral iron supplementation for iron deficiency anaemia |
|
NENC Medicines Committee (August 2024) |
| 10.02.02 |
Quinine Sulfate - addition of 200mg tablets |
|
NENC Medicines Committee (August 2024) |
| 11.04.01 |
Hydroortisone Sodium Phosphate eye drops for patients who require a preservative-free low potency ocular corticosteroid |
|
NENC Medicines Committee (August 2024) |
| 13.05.03 |
Pimecrolimus cream - additional wording to clarify initiation |
|
NENC Medicines Committee (August 2024) |
| 13.05.03 |
Tacrolimus ointment - additional wording to clarify initiation |
|
NENC Medicines Committee (August 2024) |
| 15.01.01 |
Ketamine in palliative care - changed from Amber to Red |
|
NENC Medicines Committee (August 2024) |
